Blocking LINGO-1 in vivo reduces degeneration and enhances regeneration of the optic nerve [0.03%]
遗传学方法体内抑制LINGO-1可减少视神经退行性变并促进其再生
Melissa M Gresle,Yaou Liu,Trevor J Kilpatrick et al.
Melissa M Gresle et al.
Background: Two ongoing phase II clinical trials (RENEW and SYNERGY) have been developed to test the efficacy of anti-LINGO-1 antibodies in acute optic neuritis and relapsing forms of multiple sclerosis, respectively. Acr...
Phu D Hoang,Meryem Baysan,Hilary Gunn et al.
Phu D Hoang et al.
Introduction: The Physiological Profile Assessment (PPA) is used in research and clinical practice for assessing fall risk. We compared PPA test performance between people with multiple sclerosis (MS) and healthy controls...
Differences in common heritable blood immune cell populations may underlie MS susceptibility and progression [0.03%]
常见的可遗传的血液免疫细胞群差异可能是多发性硬化易感性和进展的基础
David R Booth,Nicole L Fewings,Grant P Parnell et al.
David R Booth et al.
A promising new avenue of MS research that may lead to a better understanding of pathogenesis, progression and therapeutic response, and to development of new therapies, comes from the recent identification of defined immune cell population...
Accuracy and precision of smartphone applications and commercially available motion sensors in multiple sclerosis [0.03%]
智能手机应用程序和商用运动传感器在多发性硬化症患者中的准确性和精确度
Julia M Balto,Dominique L Kinnett-Hopkins,Robert W Motl
Julia M Balto
Background: There is increased interest in the application of smartphone applications and wearable motion sensors among multiple sclerosis (MS) patients. ...
Delayed-release dimethyl fumarate and disability assessed by the Multiple Sclerosis Functional Composite: Integrated analysis of DEFINE and CONFIRM [0.03%]
延缓释放富马酸二甲酯和由多发性硬化症功能复合评估的残疾状况：DEFINE研究与CONFIRM研究整合分析
Gavin Giovannoni,Ralf Gold,Ludwig Kappos et al.
Gavin Giovannoni et al.
The effect of delayed-release dimethyl fumarate (DMF; also known as gastro-resistant DMF) on the Multiple Sclerosis Functional Composite (MSFC) was assessed using integrated Phase 3 DEFINE and CONFIRM data. Patients treated with DMF (n = 76...
Comparison of nadir serum concentrations in the extended dosing therapy of natalizumab between American and Japanese multiple sclerosis patients [0.03%]
纳利珠单抗延长给药疗程在美国和日本多发性硬化患者中达到稳态时的谷浓度比较研究
Masami Tanaka,Kaho Yokoyama
Masami Tanaka
Geographic variations of multiple sclerosis prevalence in France: The latitude gradient is not uniform depending on the socioeconomic status of the studied population [0.03%]
法国多发性硬化患病率的地理差异：纬度梯度因研究人群的社会经济地位不同而不均匀
Philippe Ha-Vinh,Stève Nauleau,Marine Clementz et al.
Philippe Ha-Vinh et al.
Background: In France, two studies analysed multiple sclerosis prevalence nationwide: one was carried out in farmers, and the other one in employees. A south-north gradient of prevalence was found solely in farmers. ...
Negative prognostic impact of MRI spinal lesions in the early stages of relapsing-remitting multiple sclerosis [0.03%]
复发缓解型多发性硬化症早期阶段磁共振脊髓病变的不良预后影响
E D&#x;Amico,F Patti,C Leone et al.
E D&#x;Amico et al.
Background: The presence of spinal cord (SC) magnetic resonance imaging (MRI) lesions can be expected to affect the mobility of people with relapsing-remitting MS (pwRRMS), but reports are ambiguous. ...
Myelin oligodendrocyte glycoprotein has a dual role in T cell autoimmunity against central nervous system myelin [0.03%]
髓鞘少突胶质细胞糖蛋白在针对中枢神经系统髓鞘的T细胞自身免疫中的双重作用
Bert A &#x;t Hart,Robert Weissert
Bert A &#x;t Hart
Background: Myelin oligodendrocyte glycoprotein (MOG) is a candidate primary target of the autoimmune attack on the central nervous system (CNS) in multiple sclerosis (MS). However, the physiological function of MOG has b...
Longitudinal analyses of anti-JCV antibody index for risk assessment of progressive multifocal leukoencephalopathy [0.03%]
抗JCV抗体指数的纵向分析在进行进展性多灶性白质脑病风险评估中的应用
A Salmen,N von Ahsen,A K Trampe et al.
A Salmen et al.
Risk assessment for natalizumab-associated progressive multifocal leukoencephalopathy (Nat-PML) comprises the anti-JC virus (JCV) antibody index (AI). The anti-JCV AI was longitudinally determined in a natalizumab-treated MS cohort (Nat-MS,...